Accentuating cardiovascular events in Sibutramine-treated patients

Radeyah Waseem, Mahnoor Raza, Aleena Aftab

Madam, sibutramine is an anti-obesity medication that is chemically related to amphetamines. It is mainly used to manage obesity due to its appetite-suppressing effect. The drug has gained a lot of popularity since it promotes a modest weight reduction. However, Sibutramine had some undesirable side-effects, headache, constipation and nausea being the most commonly reported, followed by dizziness, xerostomia and insomnia. Even then, authorities surmised this drug to be more beneficial than harmful, and it was marketed in Pakistan.

However, a 2010 study published in The New England Journal of Medicine raised more significant concerns - it showed that Sibutramine administration caused a statistically significant rise in cardiovascular diseases. The study had a huge impact on China, Canada, Australia, Mexico, New Zealand, Thailand, the European Union, Hong Kong, the Philippines, India, the United Kingdom, and the United States dismissing Sibutramine. To further accentuate the findings, a case report was published in Acute Medicine & Surgery in 2017, which showed that Sibutramine caused a 21-year-old female without any prior history of cardiovascular disease to develop cardiac arrest.

With these findings, one can question the use of Sibutramine in Pakistan.

Anti-obesity drugs are quite popular in Pakistan since obesity is prevalent here. The findings of a study published in James Journal of Obesity & Metabolic Syndrome in March 2020 by Asif et al. demonstrated that 22.8% of the participants from the survey were overweight and 5.1% were obese. However, obesity is not the only main concern in society. Another study published in the American Heart Journal was conducted to determine the frequency of Coronary Artery Diseases (CAD) in Karachi, the most populated city of Pakistan. The prevalence of CAD was 26.9% overall, with 23.7% in men compared to 30.0% in women. The risk was uniformly higher in the young and in women. These statistics raise serious questions as to whether Sibutramine should be prescribed to a population already at a high risk of developing cardiovascular diseases should consider an alternate medicine. Physicians need to be more vigilant when prescribing this drug and ensure a proper follow-up for patients at risk.

Disclaimer: None to declare.

Conflict of Interest: None to declare.

Funding Disclosure: None to declare.

References